# Uncommon Bedfellows: Coexistent T-Cell Large Granular Lymphocytic Leukaemia and Hodgkin Lymphoma—A Case Report

**Authors:** Daniel van Tonder, Brendon Roets, Nicole Holland

PMC · DOI: 10.1155/crh/6159755 · Case Reports in Hematology · 2025-11-10

## TL;DR

A rare case of two blood cancers, Hodgkin lymphoma and T-cell large granular lymphocytic leukemia, occurring together in one patient is reported, highlighting unusual diagnostic and treatment challenges.

## Contribution

This case report documents the rare coexistence and evolution of Hodgkin lymphoma and T-LGLL, offering insights into their potential therapeutic interplay.

## Key findings

- A patient with Hodgkin lymphoma developed T-LGLL after treatment, suggesting therapy-induced clonal selection.
- Bone marrow analysis revealed biclonal T-cell populations at diagnosis, evolving to monoclonality over time.
- The case highlights the complexity of managing dual lymphoid neoplasms and the need for further research into their co-occurrence.

## Abstract

This case describes an exceptionally rare co-occurrence of Hodgkin lymphoma (HL) and T-cell large granular lymphocytic leukaemia (T-LGLL), highlighting the diagnostic and therapeutic complexity of dual lymphoid neoplasms. A 39-year-old African man presented with B symptoms and was diagnosed with stage IIIB HL and achieved remission following six cycles of doxorubicin (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy with external beam radiotherapy. At diagnosis, bone marrow evaluation revealed lymphocytosis with aberrant T-cell phenotypes and biclonality in the T-cell receptor rearrangements, suggestive of a coexistent clonal T-cell process. Following treatment, he developed persistent lymphocytosis with conversion to a monoclonal T-cell population, indicating clonal selection. Nearly 3 years later, the patient relapsed with HL, accompanied by bone marrow infiltration by large granular lymphocytes with a monoclonal, aberrant cytotoxic T-cell phenotype, consistent with T-LGLL. This case is notable for the evolution of T-LGLL in the context of relapsed HL, possibly due to therapy related selection of a pre-existing T-cell clone. Literature on the coexistence of HL and T-LGLL is sparse, underscoring the rarity of this presentation.

## Linked entities

- **Chemicals:** doxorubicin (PubChem CID 31703), bleomycin (PubChem CID 5360373), vinblastine (PubChem CID 13342), dacarbazine (PubChem CID 135398738)
- **Diseases:** Hodgkin lymphoma (MONDO:0004952), T-cell large granular lymphocytic leukaemia (MONDO:0019469), lymphoma (MONDO:0003659)

## Full-text entities

- **Diseases:** lymphocytosis (MESH:D008218), HL (MESH:D006689), stage IIIB (MESH:C566890), dual lymphoid neoplasms (MESH:D009105), T-Cell Large Granular Lymphocytic Leukaemia (MESH:D054066)
- **Chemicals:** adriamycin (MESH:D004317), bleomycin, vinblastine and dacarbazine (-), ABVD (MESH:C034632)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12623072/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12623072/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12623072/full.md

---
Source: https://tomesphere.com/paper/PMC12623072